Boehringer Ingelheim and Vanderbilt University will be extending existing collaboration to develop novel anti-cancer compounds.

The expanded research partnership will focus on the discovery and development of new chemical therapeutics targeting the pro-survival protein MCL1 as a potential therapy against MCL1 dependent cancers. This is the third collaboration between Boehringer Ingelheim and Vanderbilt University to pursue discoveries made in the laboratory of Stephen W. Fesik, Ph.D., at Vanderbilt University School of Medicine.

“Boehringer Ingelheim and Vanderbilt University have the expertise and are jointly focused on discovering breakthrough medicines against the cancer causing proteins KRAS, SOS and now, MCL1,” said Darryl McConnell, Ph.D., Vice President and Research Site Head, Boehringer Ingelheim, Austria. “Together, we are committed to driving scientific research and development forward to help patients win the fight against cancer.”

“MCL1 is one of the top ten overexpressed genes in human cancer where it plays a role as a survival factor,” said Lawrence J. Marnett, Ph.D., Dean of Basic Sciences in the Vanderbilt University School of Medicine.

“It is a great target for therapy, but candidate drugs need to disrupt high affinity protein-protein interactions, which is very challenging,” Marnett said. “The Fesik laboratory has made impressive strides in developing such compounds and it is exciting to see them advanced toward clinical development through the partnership with Boehringer Ingelheim.”

MCL1, when overexpressed, can prevent cancer cells from undergoing programmed cell death (also known as apoptosis). This necessitates the discovery of a molecule that binds extremely tightly and selectively to MCL1 in order to sufficiently induce on-target, mechanism-based cancer cell death.

This agreement between Boehringer Ingelheim and Vanderbilt University includes undisclosed upfront and milestone payments, with the ambition of delivering a new cancer drug to market as quickly as possible.  

(Source: Boehringer Ingelheim Pharmaceuticals)